Latest total revenue for DNTH: $1.4M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
As of the most recent data (June 2026), DNTH shows a total revenue of $1.4M. That compares with $2.7M in the prior-year period — down 46.3% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, DNTH's total revenue is now $1.4M (was $2.7M) — a 46.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Dianthus Therapeutics is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Dianthus Therapeutics is at $1.4M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how DNTH stacks up against individual peers as well.
Tracking DNTH's total revenue over time shows whether Dianthus Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4M That compares with $2.7M in the prior-year period — down 46.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Dianthus Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $1.4M) with ownership activity and broader fundamentals.